Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome

Crit Care. 2017 Mar 9;21(1):48. doi: 10.1186/s13054-017-1625-1.

Abstract

Background: Failure of circulating monocytes for adequate cytokine production is a trait of sepsis-induced immunosuppression; however, its duration and association with final outcome are poorly understood.

Methods: We conducted a substudy of a large randomised clinical trial. Peripheral blood mononuclear cells (PBMCs) were isolated within the first 24 h from the onset of systemic inflammatory response syndrome in 95 patients with microbiologically confirmed or clinically suspected gram-negative infections. Isolation was repeated on days 3, 7 and 10. PBMCs were stimulated for cytokine production. The study endpoints were the differences between survivors and non-survivors, the persistence of immunosuppression, and determination of admission clinical signs that can lead to early identification of the likelihood of immunosuppression.

Results: PBMCs of survivors produced significantly greater concentrations of tumour necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, IL-10, interferon-γ and granulocyte-macrophage colony-stimulating factor after day 3. Using ROC analysis, we found that TNF-α production less than 250 pg/ml after lipopolysaccharide stimulation on day 3 could discriminate patients from healthy control subjects; this was associated with a 5.18 OR of having an unfavourable outcome (p = 0.046). This trait persisted as long as day 10. Logistic regression analysis showed that cardiovascular failure on admission was the only independent predictor of defective TNF-α production on day 3.

Conclusions: Defective TNF-α production is a major trait of sepsis-induced immunosuppression. It is associated with significant risk for unfavourable outcome and persists until day 10. Cardiovascular failure on admission is predictive of defective TNF-α production during follow-up.

Trial registration: ClinicalTrials.gov identifier: NCT01223690 . Registered on 18 October 2010.

Keywords: Immunosuppression; Prediction; Sepsis; Survival.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Clarithromycin / pharmacology
  • Clarithromycin / therapeutic use
  • Decision Support Techniques
  • Female
  • Gram-Negative Bacteria / metabolism*
  • Gram-Negative Bacteria / pathogenicity
  • Granulocyte-Macrophage Colony-Stimulating Factor / analysis
  • Granulocyte-Macrophage Colony-Stimulating Factor / blood
  • Greece
  • Humans
  • Infections / blood
  • Infections / complications*
  • Interferon-gamma / analysis
  • Interferon-gamma / blood
  • Interleukin-10 / analysis
  • Interleukin-10 / blood
  • Interleukin-6 / analysis
  • Interleukin-6 / blood
  • Interleukin-8 / analysis
  • Interleukin-8 / blood
  • Leukocytes, Mononuclear / classification*
  • Leukocytes, Mononuclear / pathology
  • Logistic Models
  • Male
  • Middle Aged
  • Placebos
  • Prospective Studies
  • ROC Curve
  • Recombinant Proteins / analysis
  • Recombinant Proteins / blood
  • Statistics, Nonparametric
  • Survivors / statistics & numerical data
  • Tumor Necrosis Factor-alpha / analysis
  • Tumor Necrosis Factor-alpha / blood

Substances

  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-6
  • Interleukin-8
  • Placebos
  • Recombinant Proteins
  • TNF protein, human
  • Tumor Necrosis Factor-alpha
  • granulocyte-macrophage colony-stimulating factor, Arg(21)-
  • Interleukin-10
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Clarithromycin

Associated data

  • ClinicalTrials.gov/NCT01223690
  • ClinicalTrials.gov/NCT01223690